The 66 references in paper А. Комаров Л., Е. Московкина С. (2016) “СОВРЕМЕННЫЕ ПОДХОДЫ К СТРАТИФИКАЦИИ РИСКА БОЛЬНЫХ, ПОДВЕРГАЕМЫХ ПЛАНОВЫМ ЧРЕСКОЖНЫМ КОРОНАРНЫМ ВМЕШАТЕЛЬСТВАМ” / spz:neicon:aterotromboz:y:2016:i:2:p:65-80

1
Mohr FW, Morice MC, Kappetein AP et al. Coronary artery bypass graft surgery vs. percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet,2013, 381(9867): 629–638.
(check this in PDF content)
2
http: //www.syntaxscore.com.
(check this in PDF content)
3
Nashef SA, Roques F, Michel P, Gauducheau E, Lemeshow S, Salamon R. European system for cardiac operative risk evaluation (EuroSCORE). Eur J Cardiothorac Surg, 1999, 16(1): 9–13.
(check this in PDF content)
4
Peterson ED, Dai D, DeLong ER et al. Contemporary mortality risk prediction for percutaneous coronary intervention: results from 588,398 procedures in the National Cardiovascular Data Registry. J Am Coll Cardiol, 2010, 55(18): 1923–1932.
(check this in PDF content)
5
Byrne А, Serruys P W, Baumbach А et al. Report of a European Society of Cardiology-European Association of Percutaneous Cardiovascular Interventions task force on the evaluation of coronary stents in Europe: executive summary. Eur Heart J, 2015 Oct 7, 36(38): 2608-2620.
(check this in PDF content)
6
2014 ESC/EACTS Guidelines on myocardial revascularization The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J, 2014 Oct 1, 35(37): 2541-2619.
(check this in PDF content)
7
Гуськова Е.В., Панченко Е.П., Комаров А.Л., Добровольский А.Б., Самко А.Н. Остаточная реактивность тромбоцитов к АДФ и риск кровотечений у больных стабильной ИБС, получающих двойную антитромбоцитарную терапию в связи с плановым чрескожным коронарным вмешательством. Российский кардиологический журнал, 2015, 3 (119): 35-42.
(check this in PDF content)
8
Комаров А.Л., Илющенко Т.А., Шахматова О.О., Деев А.Д., Самко А.Н., Панченко Е.П. Сравнительная эффективность консервативного и инвазивного лечения больных со стабильной формой ишемической болезни сердца (по результатам пятилетнего проспективного наблюдения). Кардиология, 2012, 52 (8), 4-14.
(check this in PDF content)
9
Urban Р, Abizaid А, Banning А et al. Stent Thrombosis and Bleeding Complications After Implantation of Sirolimus-Eluting Coronary Stents in an Unselected Worldwide Population. A Report From the e-SELECT (Multi-Center Post-Market Surveillance) Registry. J Am Coll Cardiol, 2011, 57: 1445–1454.
(check this in PDF content)
10
Naidu SS, Polin GM, Selzer F et al. Outcome of Percutaneous Coronary Intervention in Unstable Angina Pectoris Versus Stable Angina Pectoris in Two Different Time Periods. Am J Cardiol, 2006, 98: 447–452.
(check this in PDF content)
11
Sedlis SP, Hartigan PM, Teo KK, Maron DJ, Spertus JA, Mancini GB, Kostuk W, Chaitman BR, Berman D, Lorin JD, Dada M, Weintraub WS, Boden WE, COURAGE. Trial Investigators. Effect of PCI on longterm survival in patients with stable ischemic heart disease. N Engl J Med, 2015, 373: 1937–1946.
(check this in PDF content)
12
Hueb W, Lopes N, Gersh BJ, Soares PR, Ribeiro EE, Pereira AC, Favarato D, Rocha AS, Hueb AC, Ramires JA. Ten-year follow-up survival of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. Circulation, 2010, 122(10): 949–957.
(check this in PDF content)
13
Hochman JS, Lamas GA, Buller CE, Dzavik V, Reynolds HR, Abramsky SJ, Forman S, RuzylloW, Maggioni AP, White H, Sadowski Z, Carvalho AC, Rankin JM, Renkin JP, Steg PG, Mascette AM, Sopko G, Pfisterer ME, Leor J, Fridrich V, Mark DB, Knatterud GL. Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med, 2006, 355(23): 2395–2407.
(check this in PDF content)
14
Nishigaki K, Yamazaki T, Kitabatake A, Yamaguchi T, Kanmatsuse K, Kodama I, Takekoshi N, Tomoike H, Hori M, Matsuzaki M, Takeshita A, Shimbo T, Fujiwara H. Percutaneous coronary intervention plus medical therapy reduces the incidence of acute coronary syndrome more effectively than initial medical therapy only among patients with low-risk coronary artery disease a randomized, comparative, multicenter study. JACC Cardiovasc Interv, 2008, 1(5): 469–479.
(check this in PDF content)
15
ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD The Task Force on diabetes, pre-diabetes, and cardiovascular diseases oftheEuropeanSociety of Cardiology(ESC)anddeveloped incollaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J, 2015 Oct 7, 36(38): 2608-2620.
(check this in PDF content)
16
Hlatky МА, Boothroyd DB, Bravata DM et al. Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials. Lancet, 2009, 373: 1190–1197.
(check this in PDF content)
17
Frye RL, August P, Brooks MM, Hardison RM et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med, 2009, 360(24): 2503–2515.
(check this in PDF content)
18
Subodh Verma, Michael E Farkouh, Bobby Yanagawa et al. Comparison of coronary artery bypass surgery and percutaneous coronary intervention in patients with diabetes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol, 2013, 1: 317—328.
(check this in PDF content)
19
Kappetein AP, Head SJ, Morice MC, Banning AP, Serruys PW, Mohr FW, Dawkins KD, Mack MJ, Investigators S. Treatment of complex coronary artery disease in patients with diabetes: 5-year results comparing outcomes of bypass surgery and percutaneous coronary intervention in the SYNTAX trial. Eur J Cardiothorac Surg, 2013, 43(5): 1006–1013.
(check this in PDF content)
20
http: //www.gracescore.org/WebSite.
(check this in PDF content)
21
http: //www.crusadebleedingscore.org.
(check this in PDF content)
22
ESC guidelines on the management of stable angina pectoris. Eur Heart J, 2006 Jun, 27(11): 1341-1381.
(check this in PDF content)
23
Shlipak MG, Fried LF, Cushman M et al. Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. JAMA, 2005 Apr 13, 293(14): 1737-1745.
(check this in PDF content)
24
National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. Ann Intern Med, 2003, 139: 137147.
(check this in PDF content)
25
Chertow GM, Normand SL, McNeil BJ. «Renalism»: inappropriately low rates of coronary angiography in elderly individuals with renal insufficiency. J Am SocNephrol, 2004, 15(9): 2462–2468.
(check this in PDF content)
26
Szummer K, Lundman P, Jacobson SH, Schon S, Lindback J, Stenestrand U, Wallentin L, Jernberg T. Influence of renal function on the effects of early revascularization in non-ST-elevation myocardial infarction: data from the SwedishWeb-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART). Circulation, 2009, 120(10): 851–858.
(check this in PDF content)
27
Hemmelgarn BR, Southern D, Culleton BF, Mitchell LB, Knudtson ML, Ghali WA. Survival after coronary revascularization among patients with kidney disease. Circulation, 2004, 110(14): 1890–1895.
(check this in PDF content)
28
Reddan DN, Szczech LA, Tuttle RH, Shaw LK, Jones RH, Schwab SJ, Smith MS, Califf RM, Mark DB, OwenWFJr. Chronic kidney disease, mortality, and treatment strategies among patients with clinically significant coronary artery disease. JAmSoc Nephrol, 2003, 14(9): 2373–2380.
(check this in PDF content)
29
Huang HD, Alam M, Hamzeh I, Virani S, Deswal A, Aguilar D, Rogers P, Kougias P, Birnbaum Y, Paniagua D, Kar B, Ballantyne C, Bozkurt B, Jneid H. Patients with severe chronic kidney disease benefit from early revascularization after acute coronary syndrome. Int J Cardiol, 2013, 168(4): 3741–3746.
(check this in PDF content)
30
Ashrith G, LeeVV, ElaydaMA, ReulRM, Wilson JM. Short— and long-term outcomes of coronary artery bypass grafting or drug-eluting stent implantation for multivessel coronary artery disease in patients with chronic kidney disease. Am J Cardiol, 2010, 106(3): 348–353.
(check this in PDF content)
31
Charytan DM, Li S, Liu J, Herzog CA. Risks of death and end-stage renal disease after surgical compared with percutaneous coronary revascularization in elderly patients with chronic kidney disease. Circulation, 2012, 126(11 Suppl 1): 164–169.
(check this in PDF content)
32
Ix JH, Mercado N, Shlipak MG, Lemos PA, Boersma E, Lindeboom W, O’Neill WW, Wijns W, Serruys PW. Association of chronic kidney disease with clinical outcomes after coronary revascularization: the Arterial Revascularization Therapies Study (ARTS). Am Heart J, 2005, 149(3): 512–519.
(check this in PDF content)
33
Brooks ММ, Chaitman BR, Nesto RW et al. Clinical and Angiographic Risk Stratification and Differential Impact on Treatment Outcomes in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial.
(check this in PDF content)
34
D’Agostino RB, Russell MW, Huse DM, Ellison RC, Silbershatz H, Wilson PWF, Hartz SC. Primary and subsequent coronary risk appraisal: new results from the Framingham study. Am Heart J,2000, 139: 272–281.
(check this in PDF content)
35
Ranucci M, Castelvecchio S, Menicanti L, Frigiola A, Pelissero G. Risk of assessing mortality risk in elective cardiac operations: age, creatinine, ejection fraction, and the law of parsimony. Circulation, 2009, 119(24): 3053–3061.
(check this in PDF content)
36
Wykrzykowska JJ, Garg S, Onuma Y, de Vries T, Goedhart D, Morel MA, van Es GA, Buszman P, Linke A, Ischinger T, Klauss V, Corti R, Eberli F, WijnsW, Morice MC, diMario C, van Geuns RJ, Juni P, Windecker S, Serruys PW. Value of age, creatinine, and ejection fraction (ACEF score) in assessing risk in patients undergoing percutaneous coronary interventions in the ’All-Comers’ LEADERS trial. Circ Cardiovasc Interv, 2011, 4(1): 47–56.
(check this in PDF content)
37
Peterson ED, Dai D, DeLong ER, Brennan JM, Singh M, Rao SV, Shaw RE, Roe MT, Ho KK, Klein LW, Krone RJ,Weintraub WS, Brindis RG, Rumsfeld JS, Spertus JA, Participants NR. Contemporary mortality risk prediction for percutaneous coronary intervention: results from 588,398 procedures in the National Cardiovascular Data Registry. J Am Coll Cardiol, 2010, 55(18): 1923–1932.
(check this in PDF content)
38
www.euroscore.org /calc.html.
(check this in PDF content)
39
Califf RM, Phillips HR 3rd, Hindman MC et al. Prognostic value of a coronary artery jeopardy score. J Am Coll Cardiol, 1985, 5: 1055–1063.
(check this in PDF content)
40
Ellis SG, Vandormael MG, Cowley MJ et al. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Implications for patient selection. Circulation, 1990, 82: 1193-1202.
(check this in PDF content)
41
Sianos G, Morel MA, Kappetein AP, Morice MC, Colombo A, Dawkins K, van den Brand M, Van Dyck N, Russell ME, Mohr FW, Serruys PW. The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention, 2005, 1(2): 219–227.
(check this in PDF content)
42
Levine GN, Bates ER, Blankenship JC et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol, 2011, 58: 44-122.
(check this in PDF content)
43
Serruys PW, Morice MC, Kappetein AP et al., for the SYNTAX Investigators. Percutaneous coronary intervention versus coronaryartery bypass grafting for severe coronary artery disease. N Engl J Med, 2009, 360: 961–972.
(check this in PDF content)
44
Garg S, Sarno G, Girasis C et al. A patient-level pooled analysis assessing the impact of the SYNTAX (Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery) score on 1-year clinical outcomes in 6,508 patients enrolled in contemporary coronary stent trials. J Am Coll Cardiol Interv, 2011, 4: 645–653.
(check this in PDF content)
45
Iijima R, Nagashima Y, Sato K, Tokue et al. SYNTAX score predicts major bleeding following drug-eluting stent implantation in an all-comers population. Rev Esp Cardiol(Engl Ed), 2015 Jan, 68(1): 54-62. doi: 10.1016/j.rec.2014.02.028. Epub 2014 Aug 22.
(check this in PDF content)
46
Yadav М, Palmerini Т, Caixeta А et al. Prediction of Coronary Risk by SYNTAX and Derived Scores Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery. J Am Coll Cardiol, 2013, 62: 1219–1230.
(check this in PDF content)
47
Farkouh ME, Domanski M, Sleeper LA et al., for the FREEDOM Trial Investigators. Strategies for multivessel revascularization in patients with diabetes. N Engl J Med, 2012, 367: 2375–2384.
(check this in PDF content)
48
Hochholzer W1, Trenk D, Frundi D et al. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation, 2005 May 24, 111(20): 25602564.
(check this in PDF content)
49
Aradi D, Storey R F, Komocsi A et al. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. European Heart Journal, 2014, 35: 209–215, doi: 10.1093/eurheartj/eht375.
(check this in PDF content)
50
Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. Supplementary material. http: //eurheartj.oxfordjournals.org/content/ehj/suppl/2013/08 /23/eht375.DC1/eht375supp.pdf.
(check this in PDF content)
51
Tantry US., Bonello L, Aradi D, for the Working Group on On-Treatment Platelet Reactivity. Consensus and Update on the Definition of On-Treatment Platelet Reactivity to Adenosine Diphosphate Associated With Ischemia and Bleeding. J Am Coll Cardiol, 2013, 62: 2261–2273.
(check this in PDF content)
52
Tullio Palmerini, Paolo CalabrШ, Federico Piscione, et al. Impact of Gene Polymorphisms, Platelet Reactivity, and the SYNTAX Score on 1-Year Clinical Outcomes in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention The GEPRESS Study. J Am Coll Cardiol Intv, 2014, 7: 1117–1127.
(check this in PDF content)
53
Amsterdam EA, Wenger NK, Brindis RG et al. 2014 AHA/ACC guideline for the management of patients with non_ST-elevation acute coronary syndromes: a report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol, 2014, 64: 139-228.
(check this in PDF content)
54
2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal, doi: 10.1093/eurheartj/ehv320.
(check this in PDF content)
55
Gwon HC, Hahn JY, Park KW et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. Circulation, 2012, 125: 505-513.
(check this in PDF content)
56
Feres F, Costa RA, Abizaid A et al. Three vs twelve months of dual antiplatelet therapy after zotarolimuseluting stents: the OPTIMIZE randomized trial. JAMA, 2013 Dec 18, 310(23): 2510-2522.
(check this in PDF content)
57
Kim BK, Hong MK, Shin DH et al. A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimuseluting stent implantation). J Am Coll Cardiol, 2012 Oct 9, 60(15): 1340-1348.
(check this in PDF content)
58
Colombo A, Chieffo A, Frasheri A et al. Second-generation drug-eluting stent implantation followed by 6— versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial. J Am Coll Cardiol, 2014 Nov 18, 64(20): 2086-2097.
(check this in PDF content)
59
Navarese EP, Andreotti F, Schulze V et al. Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials. BMJ, 2015, 350: doi:10.1136/bmj.h1618.
(check this in PDF content)
60
Giustino G, Baber U, Sartori S, Mehran R, Mastoris I, Kini AS, Sharma SK, Pocock SJ, Dangas GD, Duration of Dual Antiplatelet Therapy Following Drug-Eluting Stent Implantation: A Systematic Review and MetaAnalysis of Randomized Controlled Trials, Journal of the American College of Cardiology, 2015, doi: 10.1016/j.jacc.2015.01.039.
(check this in PDF content)
61
Udell JA, Bonaca MP, Collet JP et al. Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative metaanalysis of randomized trials. Eur Heart J,2016 Jan 21, 37(4): 390-399.
(check this in PDF content)
62
Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, Granger CB, Lange RA, Mack MJ, Mauri L, Mehran R, Mukherjee D, Newby LK, O’Gara PT, Sabatine MS, Smith PK, Smith Jr SC, Focused Update Writing Group, 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease, Journal of the American College of Cardiology, 2016) doi: 10.1016/j.jacc.2016.03.513.
(check this in PDF content)
63
Yeh RW, Secemsky E, Kereiakes DJ et al. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond one year after percutaneous coronary intervention: an analysis from the randomized Dual Antiplatelet Therapy Study. JAMA, 2016 Apr 26, 315(16): 1735-49.
(check this in PDF content)
64
www.daptstudy.org.
(check this in PDF content)
65
Laura Mauri, Dean J. Kereiakes, Robert W. Yeh et al. Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents. N Engl J Med, 2014, 371: 2155-2166.
(check this in PDF content)
66
Camenzind E, WijnsW, Mauri L et al. Stent thrombosis and major clinical events at 3 years after zotarolimuseluting or sirolimus-eluting coronary stent implantation. Lancet, 2012, 380(9851): 1396-1405.
(check this in PDF content)